213 related articles for article (PubMed ID: 17283171)
21. Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice.
Pfost B; Seidl C; Autenrieth M; Saur D; Bruchertseifer F; Morgenstern A; Schwaiger M; Senekowitsch-Schmidtke R
J Nucl Med; 2009 Oct; 50(10):1700-8. PubMed ID: 19793735
[TBL] [Abstract][Full Text] [Related]
22. Monte Carlo single-cell dosimetry of I-131, I-125 and I-123 for targeted radioimmunotherapy of B-cell lymphoma.
Bousis C; Emfietzoglou D; Nikjoo H
Int J Radiat Biol; 2012 Dec; 88(12):908-15. PubMed ID: 22348681
[TBL] [Abstract][Full Text] [Related]
23. Radioimmunotherapy for the intensification of conditioning before stem cell transplantation: differences in dosimetry and biokinetics of 188Re- and 99mTc-labeled anti-NCA-95 MAbs.
Kotzerke J; Glatting G; Seitz U; Rentschler M; Neumaier B; Bunjes D; Duncker C; Dohr D; Bergmann L; Reske SN
J Nucl Med; 2000 Mar; 41(3):531-7. PubMed ID: 10716329
[TBL] [Abstract][Full Text] [Related]
24. Copper-67 radioimmunotherapy and growth inhibition by anti-L1-cell adhesion molecule monoclonal antibodies in a therapy model of ovarian cancer metastasis.
Knogler K; Grünberg J; Zimmermann K; Cohrs S; Honer M; Ametamey S; Altevogt P; Fogel M; Schubiger PA; Novak-Hofer I
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):603-11. PubMed ID: 17255283
[TBL] [Abstract][Full Text] [Related]
25. The importance of antibody-specificity in determining successful radioimmunotherapy of B-cell lymphoma.
Illidge TM; Cragg MS; McBride HM; French RR; Glennie MJ
Blood; 1999 Jul; 94(1):233-43. PubMed ID: 10381518
[TBL] [Abstract][Full Text] [Related]
26. [Radioimmunotherapy with 131 I-labeled humanized anti-HBsAg Fab and anti-nucleus antigen monoclonal antibody chTNT in nude mice bearing human hepatocellular carcinoma].
DU YF; Luo RC; Li GP; Li AM; Ding XM; Yan X; Huang K
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Mar; 28(3):460-2. PubMed ID: 18359714
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of methods for red marrow dosimetry based on patients undergoing radioimmunotherapy.
Hindorf C; Lindén O; Tennvall J; Wingårdh K; Strand SE
Acta Oncol; 2005; 44(6):579-88. PubMed ID: 16165917
[TBL] [Abstract][Full Text] [Related]
28. 177Lu-antibody conjugates for single-cell kill of B-lymphoma cells in vitro and for therapy of micrometastases in vivo.
Michel RB; Andrews PM; Rosario AV; Goldenberg DM; Mattes MJ
Nucl Med Biol; 2005 Apr; 32(3):269-78. PubMed ID: 15820762
[TBL] [Abstract][Full Text] [Related]
29. Improving tumor-to-normal-tissue ratios of antibodies by extracorporeal immunoadsorption based on the avidin-biotin concept: development of a new treatment strategy applied to monoclonal antibodies murine L6 and chimeric BR96.
Tennvall J; Garkavij M; Chen J; Sjögren HO; Strand SE
Cancer; 1997 Dec; 80(12 Suppl):2411-8. PubMed ID: 9406691
[TBL] [Abstract][Full Text] [Related]
30. Susceptibility of the human pathogenic fungi Cryptococcus neoformans and Histoplasma capsulatum to gamma-radiation versus radioimmunotherapy with alpha- and beta-emitting radioisotopes.
Dadachova E; Howell RW; Bryan RA; Frenkel A; Nosanchuk JD; Casadevall A
J Nucl Med; 2004 Feb; 45(2):313-20. PubMed ID: 14960655
[TBL] [Abstract][Full Text] [Related]
31. 211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo.
Bäck T; Andersson H; Divgi CR; Hultborn R; Jensen H; Lindegren S; Palm S; Jacobsson L
J Nucl Med; 2005 Dec; 46(12):2061-7. PubMed ID: 16330571
[TBL] [Abstract][Full Text] [Related]
32. In vivo targeting of dead tumor cells in a murine tumor model using a monoclonal antibody specific for the La autoantigen.
Al-Ejeh F; Darby JM; Pensa K; Diener KR; Hayball JD; Brown MP
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5519s-5527s. PubMed ID: 17875784
[TBL] [Abstract][Full Text] [Related]
33. Radioimmunotherapy of micrometastases in lung with vascular targeted 213Bi.
Kennel SJ; Boll R; Stabin M; Schuller HM; Mirzadeh S
Br J Cancer; 1999 Apr; 80(1-2):175-84. PubMed ID: 10389994
[TBL] [Abstract][Full Text] [Related]
34. Cyclophosphamide inhibition of anti-CD40 monoclonal antibody-based therapy of B cell lymphoma is dependent on CD11b+ cells.
Honeychurch J; Glennie MJ; Illidge TM
Cancer Res; 2005 Aug; 65(16):7493-501. PubMed ID: 16103104
[TBL] [Abstract][Full Text] [Related]
35. Therapy of advanced B-lymphoma xenografts with a combination of 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab).
Mattes MJ; Sharkey RM; Karacay H; Czuczman MS; Goldenberg DM
Clin Cancer Res; 2008 Oct; 14(19):6154-60. PubMed ID: 18829494
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial.
Kraeber-Bodéré F; Faivre-Chauvet A; Ferrer L; Vuillez JP; Brard PY; Rousseau C; Resche I; Devillers A; Laffont S; Bardiès M; Chang K; Sharkey RM; Goldenberg DM; Chatal JF; Barbet J
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3973S-81S. PubMed ID: 14506196
[TBL] [Abstract][Full Text] [Related]
37. Predicting response to radioimmunotherapy from the tumor microenvironment of colorectal carcinomas.
El Emir E; Qureshi U; Dearling JL; Boxer GM; Clatworthy I; Folarin AA; Robson MP; Nagl S; Konerding MA; Pedley RB
Cancer Res; 2007 Dec; 67(24):11896-905. PubMed ID: 18089820
[TBL] [Abstract][Full Text] [Related]
38. Optimal quality (131)I-monoclonal antibodies on high-dose labeling in a large reaction volume and temporarily coating the antibody with IODO-GEN.
Visser GW; Klok RP; Gebbinck JW; ter Linden T; van Dongen GA; Molthoff CF
J Nucl Med; 2001 Mar; 42(3):509-19. PubMed ID: 11337531
[TBL] [Abstract][Full Text] [Related]
39. Radionuclides linked to a CD74 antibody as therapeutic agents for B-cell lymphoma: comparison of Auger electron emitters with beta-particle emitters.
Govindan SV; Goldenberg DM; Elsamra SE; Griffiths GL; Ong GL; Brechbiel MW; Burton J; Sgouros G; Mattes MJ
J Nucl Med; 2000 Dec; 41(12):2089-97. PubMed ID: 11138697
[TBL] [Abstract][Full Text] [Related]
40. Enhanced tumour uptake of radiolabelled antibodies by hyperthermia: Part I: Timing of injection relative to hyperthermia.
Hauck ML; Zalutsky MR
Int J Hyperthermia; 2005 Feb; 21(1):1-11. PubMed ID: 15764347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
